Current and Emerging Second‐Generation Triptans in Acute Migraine Therapy: A Comparative Review

@article{Deleu2000CurrentAE,
  title={Current and Emerging Second‐Generation Triptans in Acute Migraine Therapy: A Comparative Review},
  author={D. Deleu and Y. Hanssens},
  journal={The Journal of Clinical Pharmacology},
  year={2000},
  volume={40}
}
  • D. Deleu, Y. Hanssens
  • Published 2000
  • Medicine
  • The Journal of Clinical Pharmacology
  • Sterile neurogenic inflammation within cephalic tissue, involving vasodilation and plasma protein extravasation, has been proposed as a pathophysiological mechanism in acute migraine. The action of 5‐hydroxytryptamine (5‐HT1B/1D) agonists—so‐called triptans—on receptors located in meningeal arteries (5‐HT1B) and trigeminovascular fiber endings (5‐HT1D) has an inhibitory effect on this neurogenic inflammation. Recently, a series of second‐generation 5‐HT1B/1D agonists (almotriptan, eletriptan… CONTINUE READING
    80 Citations
    Eletriptan
    Mechanisms of action of the 5-HT1B/1D receptor agonists.
    • 132
    • PDF
    Therapies in development for the treatment of migraine
    • H. Mucke
    • Medicine
    • Expert opinion on investigational drugs
    • 2002
    • 3
    Triptans and CNS Side-Effects
    • 57
    Reassessing the contraindication of zolmitriptan and serotonin reuptake inhibitors: an evidence‐based pharmacotherapeutic case report
    • 2
    • PDF
    Triptans in pregnancy.
    • 46
    Tolerability of the Triptans
    • 24

    References

    SHOWING 1-10 OF 165 REFERENCES
    Acute migraine therapy: the newer drugs
    • 53
    Sumatriptan in the treatment of migraine
    • 26
    Rizatriptan has central antinociceptive effects against durally evoked responses.
    • 147
    5‐HT1 receptors in migraine pathophysiology and treatment
    • 80